Details for Patent: 12,552,567

« Back to Dashboard

Which drugs does patent 12,552,567 protect, and when does it expire?

Patent 12,552,567 protects OMCAZIO and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 12,552,567

Title:	Method for packaging articles in boxes and packaging device operating according to such a method
Abstract:	A method for packaging articles in a box includes the steps of depositing at least one article in a mandrel, and folding a blank around the mandrel in correspondence with at least one folding line of the blank. The blank is folded along the folding line abutting the folding line and an edge of the mandrel only for a first part of the folding line, while a second part of the folding line remains not abutted by the mandrel.
Inventor(s):	Andrea Biondi, Luca Cavazza, Ivanoe Bertuzzi, Enrico Campagnoli, Marco Ghini, Luca Borderi
Assignee:	RA Jones and Co Inc
Application Number:	US18/711,484
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 12,552,567

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,567					TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS

International Family Members for US Patent 12,552,567

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3239997
European Patent Office	4436775
Italy	202100029753
Mexico	2024006334
World Intellectual Property Organization (WIPO)	2023094972